Chapter 3 - Anna Tribe - BCL6 is a context-dependent mediator of the glioblastoma therapy response

ABSTRACT: Whole proteome analysis of LN18 cell treated with one of five DNA-damaging treatments (fractionated irradiation (IRM), temozolomide (TMZ), acute irradiation 24 hours (IRS 24h), acute irradiation 48 hours (IRS 48h) or doxorubicin (Dox)) +/- the BCL6 inhibitor FX1.

INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive Plus

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Melanie McConnell   Paul Teesdale-Spittle  

PROVIDER: MSV000090274 | MassIVE |

REPOSITORIES: MassIVE